Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Vijay Chopra Added: 8 months ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps… View more
Dr Thomas Kahan is Senior consultant in cardiolgy at the Department of cardiology, Danderyd University Hospital Dr Kahan is on the Editorial Board of European Cardiology Review. Research Interests Neurohormonal control of blood pressure and cardiac function in man. Specifically, we study how the sympatho-adrenal mechanisms and the renin-angiotensin-aldosterone system influence… View more
Author(s): Thomas Modine Added: 8 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more
Author(s): Óscar Cano, Marek Jastrzębski, Pugazhendhi Vijayaraman Start date: Nov 13, 2024
Conduction System Pacing: Recent Advances and Clinical ApplicationsConduction system pacing (CSP) has significantly evolved in recent years, expanding from His bundle pacing to include left bundle branch pacing and left ventricular septal pacing. This webinar, led by Dr Pugazhendhi Vijayaraman, a renowned expert in the field, features presentations from esteemed faculty, Prof Marek Jastrzębski… View more
Added: 5 months ago Source:  Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The… View more